JAK2 and myeloproliferative neoplasm: Addiction of mutant JAK2-V617F MPN cells to HSP90 might be responsible for their greater sensitivity to HSP90 inhibition compared to cells expressing only wild-type JAK2, which may be important with respect to a therapeutic window in patients.